Adfrar 20 mg PFS Injection 0.4 ml

Adfrar 20 mg PFS Injection 0.4 ml belongs to the class of monoclonal TNF (Tumor necrosis factor) inhibitors that help reduce signs and symptoms of autoimmune disorders. It is primarily used in the treatment of rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, and psoriatic arthritis. This medicine is also used in the treatment of Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

Adfrar 20 mg PFS Injection 0.4 ml consists of Adalimumab, which works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive. This helps reduce inflammation and pain caused by various autoimmune diseases.

Adfrar 20 mg PFS Injection 0.4 ml may cause certain side effects such as nausea, headache, back pain, upper respiratory tract infections, vision problems, dizziness, pale skin, numbness, chest pain, rash, and injection site reactions. Most of these side effects do not require medical attention or resolve over time. However, if these side effects persist for longer, please consult your doctor on priority. Adfrar 20 mg PFS Injection 0.4 ml is a parenteral medicine. It will be administered by a trained healthcare doctor. Hence, do not self-administer. Your physician will decide the dose and duration of the medicine based on the type and severity of the condition.

Adfrar 20 mg PFS Injection 0.4 ml should be avoided if you are allergic to any of its components.  Inform your doctor if you have any history of serious infections, tuberculosis, optimistic infections, cancer, alcoholic hepatitis, hepatitis B virus infection, heart failure, liver, heart, or kidney diseases, or a weak immune system, as it can worsen your health condition. Adfrar 20 mg PFS Injection 0.4 ml may cause dizziness, so drive only if you are alert and focused. Adfrar 20 mg PFS Injection 0.4 ml should not be given to children under two years of age as safety has not been established. Consult the doctor if you are pregnant or breastfeeding.

Adfrar 20 mg PFS Injection 0.4 ml consists of Adalimumab, which belongs to the class of monoclonal TNF (Tumor necrosis factor) inhibitors. It works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive. This helps reduce inflammation and pain, redness, and inflammation (swelling) caused by various autoimmune diseases.

• Tingling or numbness
• Shortness of breath
• Vision problems
• Injection site reactions
• Headache
• Nausea
• Upper respiratory tract infections.
• Chest pain

Adfrar 20 mg PFS Injection 0.4 ml should be avoided if allergic to it or any other components present. Inform your doctor if you have any history of serious infections, tuberculosis, optimistic infections, cancer, alcoholic hepatitis, hepatitis B virus infection, heart failure, liver, heart or kidney diseases, weak immune system, multiple sclerosis (nerve and muscle disease), or diabetes as it can worsen your health condition. Do not take live vaccines while being treated with Adfrar 20 mg PFS Injection 0.4 ml to prevent any serious consequences. Adfrar 20 mg PFS Injection 0.4 ml is not recommended for use in children below two years of age as safety and efficacy are not established. This medicine is not recommended for patients suffering from sepsis as it can worsen the condition.

• Exercising regularly helps in muscle stretching that is less likely to spasm, tear and sprain. Mild exercises such as jogging and walking are helpful for muscle stretching.
• Massages can also be helpful.
• Avoid freezing and hot temperatures.
• Avoid wearing tight-fitting clothes; instead, wear loose garments.
• Rest well and get plenty of sleep.
• Stay hydrated; drink plenty of water.